Introduction {#s1}
============

Obesity, especially among children and adolescents, is a major health challenge in developed and developing countries ([@B1]--[@B3]). It is also an important risk factor for the development of metabolic diseases, including diabetes mellitus (DM) and hypertension, as well as an increase in serum total cholesterol (TC) and triglycerides (TG) ([@B4]). Despite this fact, some studies recognized non-obese individuals with metabolic abnormality---for instance, low high-density lipoprotein-cholesterol (HDL-C), high TG and TC ([@B5], [@B6]). These subjects were known as metabolically non-healthy non-obese (MNHNO). On the other hand, some evidence exists on obese patients without any type of metabolic disorders, they are considered as metabolically healthy obese (MHO) group ([@B7]--[@B9]). It is reported that the prevalence of metabolic syndrome (MetS) is 29.2% in obese children ([@B10]).

Vitamin D plays numerous extra-skeletal roles and functions. This fat-soluble vitamin has an inverse association with insulin resistance, obesity, and MetS. It is shown that individuals in the MHO group had a higher concentration of serum 25-hydroxyvitamin D than the metabolic non-healthy obese (MNHO) group ([@B11], [@B12]). However, data regarding serum vitamin D level and metabolic phenotypes of obesity among children and adolescents are limited. The current findings are controversial, and some studies did not show any significant association between vitamin D and various metabolic phenotypes of obesity ([@B13], [@B14]). Different variables as age, gender, and habitat might influence the reports of such association in adolescents; therefore, more studies are needed in this field ([@B15]). This study aimed to investigate the prevalence of obesity subsets and their relationships with serum 25-hydroxyvitamin D among Iranian children and adolescents.

Materials and Methods {#s2}
=====================

Study Population
----------------

This cross-sectional study was conducted as part of the fifth phase of a national school-based survey entitled "Childhood and Adolescence Surveillance and Prevention of Adult Non-communicable Disease" (CASPIAN-V study), which has been described in detail previously ([@B16]). The protocol of this study was mainly based on the World Health Organization-Global School Student Health Survey. Briefly, 14,400 students aged 7--18 years from primary and secondary schools in urban and rural areas of 30 provinces throughout the Iran were selected using multistage, stratified cluster sampling method in 2015 (March to May). The number of selected boys and girls was the same in each province, and the sample size in urban and rural areas was proportional to the number of students in different areas. In the next step, 4,200 students were randomly selected for biochemical tests, from which 2,594 samples have been assessed for 25-hydroxyvitamin D status. This study was conducted according to the guidelines of the Declaration of Helsinki. After explaining the study objectives and methods, written informed consent and verbal assent were obtained from all parents and students, respectively. The study protocol was reviewed and approved by the Research and Ethics Council of the National Institute for Medical Research Development (NIMAD) (project number: 194049).

Questionnaires
--------------

The demographic questionnaire was completed for the pediatric age group. All students were asked about the consumption of vitamin D supplements. The screen time (ST) was assessed as the average number of hours per day spent watching television or videos, using their personal computer, or playing electronic games by a validated questionnaire ([@B17]). According to the international ST recommendations, ST was classified into two groups (low: \<2 h per day and high: equal or more than 2 h per day ([@B18]).

Physical activity (PA) of students in the prior week was assessed using a validated questionnaire. Participants reported the frequency of their leisure-time physical activity outside of school, which caused heavy sweating or large increases in breathing or heartrate and lasted at least 30 min. PA was categorized into two groups (low: 0--3 days per week and high: 4--7 days per week) ([@B17]). For calculating the family\'s socioeconomic status (SES), questions about the parental occupational status, parental level of education, school type (public/private), having a private car, and possessing a personal computer were included in the questionnaire. SES was classified into three levels (low/moderate/high).

Anthropometric Measurements and Laboratory Tests
------------------------------------------------

Trained healthcare providers conducted anthropometric measurements. Height was measured in a standing position without shoes to the nearest 0.5 cm. Weight was measured on a digital scale (SECA, Germany) placed on flat ground with minimal clothing and without shoes to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by square of height (m^2^). Waist circumference (WC) was measured at the midpoint between the lower margin of the rib cage and top of the iliac crest at the end of normal expiration using a non-elastic tape with 0.1 cm accuracy ([@B19]). Blood pressure (BP) was measured twice with a 5-min interval on the right arm in a sitting position, using a standardized mercury sphygmomanometer. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were considered as the first and fifth Korotkoff sounds, respectively. The average of two measurements was considered as the BP.

Fasting blood samples were collected in the morning after 12--14 h of overnight fasting from all students. Biochemical variables, including fasting blood glucose (FBG), TC, HDL-C, and TG were measured enzymatically by Hitachi auto-analyzer (Tokyo, Japan) ([@B20]). The serum concentration of 25-hydroxyvitamin D was measured by a direct competitive immunoassay chemiluminescent method using LIASON 25-hydroxyvitamin D assay TOTAL (DiaSorin, Inc.) with a coefficient of variation (CV) of 9.8%.

Diagnostic Criteria
-------------------

The World Health Organization (WHO) growth curves were used for BMI classification of pediatrics. General obesity in students was defined as age and sex-specific BMI more than 95th percentile, overweight was defined as age and sex-specific BMI between the 85th to 95th percentiles, and normal weight was defined as age and sex-specific BMI between the 5th to 85th percentiles. According to the Adult Treatment Panel III (ATP III) criteria with modification for the child age group, MetS was defined as the presence of three or more of the following components: (1) serum TG concentration of 150 mg/dl or greater; (2) serum HDL-C concentration of 40 mg/dL or less; (3) serum FBG level of 100 mg/dl or greater; (4) abdominal obesity defined as waist to height ratio \> 0.5; and (5) either SBP or DBP greater than the 90th percentile for age, sex, and height ([@B21]). Students were classified into four metabolic phenotypes of obesity based on their BMI and metabolic status: (1) metabolically healthy non-obese (MHNO): normal weight pediatrics who is characterized by the absence of MetS; (2) MHO: obese pediatrics who is characterized by the absence of MetS; (3) MNHO: obese children with metabolic syndrome; (4) MNHNO: normal-weight children with MetS ([@B22]). A serum 25-hydroxyvitamin D level of \<10 ng/mL was defined as vitamin D deficiency, between 10 and 30 ng/mL as vitamin D insufficiency, and more than 30 ng/mL as vitamin D sufficiency. For purposes of the analysis, we defined hypovitaminosis D as 25-hydroxyvitamin D \<30 ng/mL, because this is a recognized cutoff for healthy vitamin D concentrations ([@B23]--[@B25]).

Statistical Analysis
--------------------

All variables were checked for normality and are presented as median (inter-quartile range), mean (standard deviation), or number (percentage). Demographic characteristics and metabolic phenotypes of obesity were compared according to gender, using independent sample *t*-test, Mann-Whitney test, and Chi-square test. The prevalence of hypovitaminosis D was compared among different metabolic phenotypes of obesity by the Chi-square test. Association of hypovitaminosis D with different metabolic phenotypes of obesity was examined using nominal logistic regression analysis adjusted for potential confounders, including age, sex, living area, screen time, and SES, physical activity, and vitamin D supplementation. Results are presented as odds ratios (OR) with a 95% confidence interval (CI). Multinomial logistic regression analysis was performed for evaluating the association of 25-hydroxyvitamin D concentration with different metabolic phenotypes of obesity. Three models were defined: Model I represented the crude association without any adjustment; Model II adjusted for age, sex, and living place; and Model III additionally adjusted for ST, PA, SES, and vitamin D supplementation. Data analysis was performed using STATA version 11.0 (STATA Statistical Software: Release 11. StataCorp LP. Package, College Station, TX, USA). *P*-value of less than 0.05 was considered as statistically significant.

Results {#s3}
=======

A total of 2,596 children and adolescents aged 7--18 years were included in this study. Overall, the mean (SD) age was 12.2 (3.1) years; 44.9% (*n* = 1,166) were girls, and 71.3% (*n* = 1,850) were urban residents. The median (interquartile range) of 25-hydroxyvitamin D was 26.49 (10.0); 71.1% (817) of subjects had hypovitaminosis D. MHNO was identified in 2,211 (85.2%), MHO in 285 (11.0%), MNHNO in 64 (2.5%), and MNHO in 34 (1.3 %) subjects ([Figure 1](#F1){ref-type="fig"}).

![Prevalence of different metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN-V study (*n* = 2,594). MHNO, metabolically healthy non obese; MHO, metabolically healthy obese; MNHNO, metabolically non healthy non obese; MNHO, metabolically non healthy obese.](fendo-11-00310-g0001){#F1}

[Table 1](#T1){ref-type="table"} presents the demographic characteristics and metabolic phenotypes of obesity according to gender. There was a significant difference between boys and girls in terms of obesity phenotypes (*p* = 0.009); a higher percentage of boys and girls had MHNO (83.5 and 87.4% respectively), and the lowest percentage was MNHO (1.7% in boys and 0.9% in girls). Serum 25-hydroxyvitamin D concentration and prevalence of hypovitaminosis D were not statistically different between boys and girls (both *p*-values \> 0.05).

###### 

Demographic characteristics and metabolic phenotypes of obesity according to gender: the CASPIAN-V study.

  **Variable**                                                                    **Girls *N* = 1,166**   **Boys *N*= 1,430**   ***p*-value**
  ------------------------------------------------------------------------------- ----------------------- --------------------- ---------------
  **Age (years)[^a^](#TN1){ref-type="table-fn"}**                                 12.0 (3.1)              12.3 (3.0)            0.006
  **Living area[^b^](#TN2){ref-type="table-fn"}**                                                                               
  Urban                                                                           828 (71.0)              1022 (71.5)           0.79
  Rural                                                                           338 (29.0)              408 (28.5)            
  **Obesity phenotype[^b^](#TN2){ref-type="table-fn"}**                                                                         
  MHNO                                                                            1,019 (87.4)            1,192 (83.5)          0.009
  MHO                                                                             106 (9.1)               179 (12.5)            
  MNHNO                                                                           31 (2.7)                33 (2.3)              
  MNHO                                                                            10 (0.9)                24 (1.7)              
  **25-hydroxyvitamin D concentration (ng/mL)[^c^](#TN3){ref-type="table-fn"}**   25.62 (10.51)           26.83 (9.00)          0.33
  **Vitamin D status[^b^](#TN2){ref-type="table-fn"}**                                                                          
  Hypovitaminosis                                                                 817 (70.1)              1,029 (72.0)          0.29
  Normal                                                                          349 (29.9)              401 (28.0)            
  **Vitamin D supplement use[^b^](#TN2){ref-type="table-fn"}**                    42 (3.6)                44 (3.1)              0.45
  **Physical activity**                                                                                                         
  Low                                                                             699 (60.3)              777 (54.6)            0.004
  High                                                                            461 (39.7)              647 (45.4)            
  **Screen time[^b^](#TN2){ref-type="table-fn"}**                                                                               
  Low                                                                             985 (86.40)             1,179 (84.8)          0.24
  High                                                                            155 (13.6)              212 (15.2)            
  **SES[^b^](#TN2){ref-type="table-fn"}**                                                                                       
  Low                                                                             403 (36.6)              405 (29.4)            \<0.001
  Moderate                                                                        331 (30.1)              496 (36.0)            
  High                                                                            366 (33.3)              477 (34.6)            

*Vitamin D insufficiency: 25-hydroxyvitamin D \<30 ng/mL*.

*MHNO, metabolically healthy non obese; MHO, metabolically healthy obese; MNHNO, metabolically non healthy non obese; MNHO, metabolically non healthy obese; SES, socioeconomic state*.

*are presented as mean (SD) and compared using t-test*.

*are presented as number (percentage) and compared using Chi-square test*.

*are presented as median (inter-quartile range) and compared using Mann--Whitney test*.

As shown in [Figure 2](#F2){ref-type="fig"}, the prevalence of vitamin D deficiency had a significant difference among different metabolic phenotypes of obesity (*p* \< 0.001); it was more prevalent in MNHO (85.3%) than in other phenotypes.

![Prevalence of hypovitaminosis D according to different metabolic phenotypes of obesity in Iranian children and adolescents: the CASPIAN-V study. MHNO, metabolically healthy non obese; MHO, metabolically healthy obese; MNHNO, metabolically non healthy non obese; MNHO, metabolically non healthy obese.](fendo-11-00310-g0002){#F2}

Based on the crude model of nominal logistic regression, serum 25-hydroxyvitamin D \<30 ng/mL significantly increased odds of being MHO rather than being MHNO by 1.39 times (95% CI: 1.05--1.86); this association was not changed after adjustment for other variables. Besides, according to the adjusted model for ST, PA, SES, and vitamin D supplementation, serum 25-hydroxyvitamin D \<30 ng/mL significantly increased odds of being MNHO rather than being MHNO by 2.89 times (95 % CI: 1.05--8.31). There was no significant association between hypovitaminosis D and other metabolic phenotypes of obesity ([Table 2](#T2){ref-type="table"}).

###### 

Association of hypovitaminosis D with different metabolic phenotypes of obesity in nominal logistic regression: the CASPIAN-V study.

                          **Metabolic phenotypes of obesity**                                                                            
  ----------------------- ------------------------------------- ---------------------------------------------------- ------------------- ----------------------------------------------------
  **Hypovitaminosis D**                                                                                                                  
  Model I                 Reference                             1.39 (1.05--1.86)[^\*^](#TN4){ref-type="table-fn"}   1.53 (0.84--2.79)   2.48 (0.95--6.45)
  Model II                Reference                             1.37(1.30--1.83)[^\*^](#TN4){ref-type="table-fn"}    1.51 (0.83--2.75)   2.44 (0.94--6.35)
  Model III               Reference                             1.46(1.07--1.77)[^\*^](#TN4){ref-type="table-fn"}    1.29 (0.70--2.39)   2.89 (1.05--8.31)[^\*^](#TN4){ref-type="table-fn"}

*Hypovitaminosis D: 25-hydroxyvitamin D \<30 ng/mL*.

*The model I: crude association; Model II: adjust for age, gender, living place; Model III: adjust for ST, PA, SES, and vitamin D supplementation. MHNO, metabolically healthy non-obese; MHO, metabolically healthy obese; MNHNO, metabolically non healthy non-obese; MNHO, metabolically non-healthy obese*.

*Values are reported as OR (95% CI)*.

*Statistically significant (p \< 0.05)*.

As presented in [Table 3](#T3){ref-type="table"}, each unit increase in serum 25-hydroxyvitamin D concentration significantly decrease the odds of being MHO, MNHO, and MNHNO by 2, 4, and 8%, respectively. Similar associations were also observed in the adjusted model for age, gender, and living area, but in the multivariate model (Model III), the association between 25-hydroxyvitamin D concentration and MHO did not reach statistical significance.

###### 

Association of vitamin D concentration with different metabolic phenotypes of obesity in nominal logistic regression: the CASPIAN-V study.

                                        **Metabolic phenotypes of obesity**                                                                                                             
  ------------------------------------- ------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  **Vitamin D concentration (ng/mL)**                                                                                                                                                   
  Model I                               Reference                             0.98 (0.97--0.99)[^\*^](#TN5){ref-type="table-fn"}   0.92 (0.90--0.95)[^\*^](#TN5){ref-type="table-fn"}   0.96 (0.92--0.99)[^\*^](#TN5){ref-type="table-fn"}
  Model II                              Reference                             0.97 (0.97--0.99)[^\*^](#TN5){ref-type="table-fn"}   0.93 (0.90--0.95)[^\*^](#TN5){ref-type="table-fn"}   0.95 (0.92--0.98)[^\*^](#TN5){ref-type="table-fn"}
  Model III                             Reference                             0.99 (0.98--1.01)                                    0.93 (0.91--0.96)[^\*^](#TN5){ref-type="table-fn"}   0.94 (0.91--0.98)[^\*^](#TN5){ref-type="table-fn"}

*Model I: crude association; Model II: adjust for age, sex, living place; Model III: adjust for ST, PA, SES, vitamin D supplementation*.

*MHNO, metabolically healthy non obese; MHO, metabolically healthy obese; MNHNO, metabolically non healthy non obese; MNHO, metabolically non healthy obese*.

*Values are reported as OR (95% CI)*.

*Statistically significant (p \< 0.05)*.

*OR calculated per each unit (ng/mL) increment in vitamin D concentration*.

Discussion {#s4}
==========

To the best of our knowledge, the current study is the first nationwide study of its kind, not only in Middle Eastern countries, but also in developing countries. The present study evaluated the relationship between vitamin D status and various metabolic phenotypes of obesity. Our data indicated that vitamin D status and metabolic health have significant interaction in children and adolescents. The prevalence of hypovitaminosis D was markedly lower in the MNHO group, compared to those in the MHNO group. Moreover, the prevalence of hypovitaminosis D was significantly higher among MNHO, followed by MNHNO and MHO groups. In adjusted logistic regression models, hypovitaminosis D significantly increased the odds of MNHO, MNHNO, and MHO, respectively. These findings were in line with the previous studies ([@B26]--[@B29]). Hypovitaminosis D showed a slightly stronger association with MNHO than other phenotypes of obesity. This finding was in contrast to Minambres et al. study, which showed that association of vitamin D and MetS is independent of the degree of obesity ([@B30]). The main hypotheses that can justify the association of hypovitaminosis D with obesity and MetS are less exposure to sunlight, an inadequate intake of vitamin D, and decreased bioavailability of vitamin D ([@B31]).

There is some controversy regarding the relationship between 25-hydroxyvitamin D concentrations and different metabolic phenotypes of obesity. Some studies showed that vitamin D deficiency was related to a higher risk of diabetes, cardiovascular diseases, and cardiometabolic risk factors among adolescents by elevated the prevalence of adiposity ([@B32]--[@B35]). Inversely, Hong et al. did not find any significant difference in vitamin D levels between MHO and MNHO groups ([@B8]). The same result was found among 8-18-year African-Caribbean-American children and adolescents, showing no significant relationship between vitamin D and phenotypes of metabolic obesity ([@B15]). Our findings are in line with a previous study in Iranian adults that showed significant differences between metabolic phenotypes of obesity and 25-hydroxyvitamin D concentration. However, contrary to that study, we found that the MHO group had significantly higher 25-hydroxyvitamin D concentration than other groups. In our study, the latter was observed in the MHNO group. Besides, the study in Iranian adults found a significant relationship between vitamin D status and cardiometabolic risk factors ([@B36]).

Nevertheless, it should be noted that unhealthy metabolic profile had a bidirectional association to decrease in vitamin D and obesity related to at least five risk factors of MetS ([@B36], [@B37]). Our study is in agreement with the study of the Third National Health and Nutrition Examination Survey (NHANES III) that found a significant relationship between vitamin D and metabolic health. It also demonstrated that vitamin D was inversely associated with cardiometabolic mortality in MNHO young adults, as well as with a decrease in the prevalence of adiposity in children ([@B38], [@B39]). Although hypovitaminosis D is observed in obese individuals, it is shown that vitamin D supplementation did not have an association with weight reduction ([@B40]). Our findings are in agreement with this study showing that an increase in 25-hydroxyvitamin D increased the odds of being MNHNO. Moreover, no or weak association was found between serum 25-hydroxyvitamin D and cardiometabolic risk factors, and the relationship between 25-hydroxyvitamin D and TC was observed only in the obese groups ([@B13], [@B14], [@B41], [@B42]). Consistently, our study showed hypovitaminosis D increased the odds of metabolic health obesity rather than other groups even after adjusting for gender, living area, physical activity, ST, and SES. Inconsistent with some other studies, a Korean study showed a negative association between vitamin D concentration and elevated fasting blood sugar ([@B13]). One of the reasons for this debate and controversy between studies may be because of differences in various definitions used for metabolic phenotypes of obesity. Another reason can be the difference in ethnicity, living region, and race that might affect 25-hydroxyvitamin D concentrations; moreover, it can be affected by body fat distribution and definition of obesity and metabolic obesity subgroups.

Furthermore, the current study addressed the prevalence of different metabolic phenotypes of obesity in Iranian children and adolescents. The prevalence of MHNO was higher than other groups, followed by MHO, MNHNO, and MNHO, respectively. This finding was in line with previous studies in Iranian children and adolescents ([@B43], [@B44]).

The prevalence of various metabolic phenotypes of obesity was different according to age, race, living area, occupation, and the definition of risk factors ([@B45]--[@B47]). Therefore, according to the previous studies, the prevalence of MHO varied from 10 to 40% among adults ([@B8], [@B48], [@B49]). Besides, among obese boys and girls, the prevalence of MHO ranged from 3% in African-Americans to about 47.7% in Koreans ([@B8], [@B49]--[@B51]). It is also showed that among 8--18 year-old pupils, the frequency of MHO was 20--53% ([@B15], [@B52], [@B53]). We suggest that as in the current study, the individuals\' characteristics and ethnicity were different than other studies; the prevalence of MHO was lower than this range. According to the above-mentioned studies, the Asian population showed a higher number of MHO than Western people; however, our findings in Iranian children and adolescents, as an Asian country, are not consistent with this issue.

The large sample size is one of the main strengths of this study. To the best of our knowledge, the current study is the first nationwide study in this field, not only in the Middle East, but also in developing countries. Thus, future studies are needed to have a better understanding of this interaction in various ethnic populations.

The main limitation of our study is the cross-sectional nature of the data. The other limitation is that the groups of obesity phenotypes did not have homogeny, as the MNHNO and MNHO groups had a small sample size. Moreover, we could not examine the pubertal status of participants in our school-based study, and puberty influences the variables assessed in our study. Measurement of 25-hydroxyvitamin D using immunoassay chemiluminescent method is another limitation of this study.

This is an association study that cannot provide causation. Randomized trials and longitudinal studies would be required to assess if treatment/supplementation with vitamin D could improve the metabolic profile of various obesity phenotypes.

In conclusion, our study examined the four subsets of metabolic obesity and 25-hydroxyvitamin D concentration as an associated factor on metabolic phenotypes of obesity in Iranian pediatric population. According to our results, we found hypovitaminosis D is related to an increase in odds of MHO, and an increase in 25-hydroxyvitamin D concentration declines the odds of MHO, MNHNO, and MNHO, significantly. The study on different metabolic phenotypes of obesity, especially in metabolically abnormal groups of obesity in children and adolescents, can be useful to evaluate the difference of metabolic obesity subgroups and the related factors. It can be of help for efficient prevention and treatment guidelines, as well as and strategies and modify lifestyle.
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